Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities

SALT LAKE CITY, TORONTO & MONTRÉAL (May 8, 2023) – Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.  “Recursion has pioneered the massive, parallel generation of -omics data with […]

Cyclica teams up with Uruguay national research agency, ANII, to enhance scientific innovation

09  March  2023, Toronto, Canada and Montevideo, Uruguay – Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and the National Research and Innovation Agency (“Agencia Nacional de Investigación e Innovación” or ANII”), a Uruguayan government agency that funds and promotes research and innovation initiatives,  announce a […]

Cyclica receives CAD$2.4M grant for a multi-targeted drug discovery program to advance non-hormonal contraceptive medicines

Cyclica receives a grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform to discover new therapeutic options for multiple low-data biological targets with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries. TORONTO, CANADA — November 15, 2022: Cyclica Inc., a neo-biotech […]